Dr. Misiukiewicz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1190 5th Avenue
New York, NY 10029Phone+1 212-241-6756Fax+1 212-659-5599
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2006 - 2009
Rutgers Health/Cooperman Barnabas Medical CenterResidency, Internal Medicine, 2003 - 2006
Wroclaw Medical UniversityClass of 1999
Certifications & Licensure
NY State Medical License 2006 - 2025
NJ State Medical License 2004 - 2019- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cabazitaxel - PF Induction Chemotherapy Start of enrollment: 2011 Apr 01
- Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
- Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2022 Jun 16
Roles: Sponsor-Investigator, Contact, Principal Investigator
Publications & Presentations
PubMed
- 31 citationsImpact of obesity on outcomes for patients with head and neck cancer.Daniel F. Hicks, Richard L. Bakst, John Doucette, Benjamin H. Kann, Brett A. Miles
Oral Oncology. 2018-08-01 - 1618 citationsPembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a ...Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara
Lancet. 2019-11-23 - 966 citationsPembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, p...Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra
Lancet. 2019-01-12
Press Mentions
New Treatments, New Outcomes for Refractory Thyroid CancerJuly 10th, 2019
Experimental Drug Selumentinib Shows Promise for Disfiguring Tumor ConditionDecember 29th, 2016
Immune-Based Treatment May Fight Advanced Cervical Cancer - US NewsJune 2nd, 2014- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
